« Back
Home /
Sivelestat

Sivelestat

Item no.	HY-17443-100mg
Manufacturer	MedChem Express
CASRN	127373-66-4
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Oncology Cardiovascular Research Atherosclerosis Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer
Type	Inhibitors
Specific against	other
Purity	99.34
Citations	[1]Kawabata K, et al. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun. 1991 Jun 14;177(2):814-20.\|[2]Yuichiro Toda, et al. A neutrophil elastase inhibitor, sivelestat, ameliorates lung injury after hemorrhagic shock in rats. Int J Mol Med. 2007 Feb;19(2):237-43.\|[3]Tomoharu Kono, et al. Neutrophil elastase inhibitor, sivelestat sodium hydrate prevents ischemia-reperfusion injury in the rat bladder. Mol Cell Biochem. 2008 Apr;311(1-2):87-92.\|[4]Adeleh Sahebnasagh, et al. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. J Clin Pharm Ther. 2020 Aug 28. Biofabrication. 2021 Apr 8;13(3):10.1088/1758-5090/abe1cf. Brain Behav Immun. 2024 Jun 12:120:403-412. Burns Trauma. 2021 Sep 17:9:tkab030. Cancers (Basel). 2022 Jan 20;14(3):515. Cell Biosci. 2022 Jul 22;12(1):114. Ecotoxicol Environ Saf. 2023 Dec:268:115694. Elife. 2022 Mar 23:11:e77444. Exp Mol Med. 2024 Dec;56(12):2602-2616. Exp Mol Med. 2025 Sep;57(9):2067-2082. FASEB J. 2024 Dec 15;38(23):e70238. Heliyon. 2024 Oct 5;10(19):e38895. Int Immunopharmacol. 2025 Jul 31:163:115276. J Cell Mol Med. 2022 Apr;26(7):2089-2103. J Exp Med. 2023 Sep 4;220(9):e20221751. J Infect Dis. 2024 May 15;229(5):1352-1365. J Tissue Eng. 2025 Aug 19:16:20417314251348038. Nat Commun. 2025 Feb 5;16(1):1378. Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. PLoS One. 2025 Nov 6;20(11):e0336333. Res Sq. 2024 Jul 30. Res Sq. 2025 May 08. Research Square Preprint. 2021 Aug. Research Square Preprint. 2021 Jun. Research Square Preprint. 2023 Dec 11. J Hepatocell Carcinoma. 2021 May 20:8:451-465. J Neuroinflammation. 2025 Aug 26;22(1):206. Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. Oxid Med Cell Longev. 2019 Nov 23;2019:7323986.
Smiles	CC(C)(C)C(OC1=CC=C(S(=O)(NC2=CC=CC=C2C(NCC(O)=O)=O)=O)C=C1)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	EI546,LY544349,ONO5046
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Elastase; SARS-CoV
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	434.46
Product Description	Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19[1][2][3][4].
Manufacturer - Research Area	Cancer
Solubility	DMSO : ≥ 100 mg/mL\|Ethanol : 3.03 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; Metabolic Enzyme/Protease
Clinical information	Launched
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.